Trade

with

Bristol-Myers Squibb Co
(NYSE: BMY)
AdChoices
53.63
+1.13
+2.15%
After Hours :
53.68
+0.05
+0.09%

Open

52.56

Previous Close

52.50

Volume (Avg)

9.03M (5.84M)

Day's Range

52.48-54.36

52Wk Range

46.30-57.49

Market Cap.

88.91B

Dividend Rate (Yield )

1.44 (2.69%)

Beta

0.43

Shares Outstanding

1.66B

P/E Ratio (EPS)

33.22 (1.61)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 16.39B

    • Net Income

    • 2.56B

    • Market Cap.

    • 88.91B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 16.59

    • PEG (Price/Earnings Growth) Ratio

    • 1.97

    • Beta

    • 0.43

    • Forward P/E

    • 31.95

    • Price/Sales

    • 5.52

    • Price/Book Value

    • 5.80

    • Price/Cash flow

    • 21.60

      • EBITDA

      • 3.85B

      • Return on Capital %

      • 7.71

      • Return on Equity %

      • 18.10

      • Return on Assets %

      • 7.71

      • Book Value/Share

      • 9.24

      • Shares Outstanding

      • 1.66B

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.36 (10/1/2014)

      • Dividend Declaration Date

      • 9/16/2014

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 50.00

        • Credit Rating

        • AA-

        • Analysts

        • 5

        • EPS Estimate

        • 1.59

        • Cashflow Estimate

        • 1.99

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -3.90

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • 30.80

          • 7.80

          • Net Income

            Q/Q (last year)

          • -37.90

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • -4.47

          • 6.10

          • Net Income

            5-Year Annual Average

          • -4.10

          • 3.73

          • Dividends

            5-Year Annual Average

          • 2.60

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 72.81

            • 69.92

            • Pre-Tax Margin

            • 19.25

            • 21.84

            • Net Profit Margin

            • 16.59

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • 73.00

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 24.90

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • 23.30

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.48

              • 0.32

              • Current Ratio

              • 1.80

              • 1.92

              • Quick Ratio

              • 1.31

              • 1.31

              • Interest Coverage

              • 16.68

              • 17.64

              • Leverage Ratio

              • 2.19

              • 2.03

              • Book Value/Share

              • 9.24

              • 14.62

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 33.22

                • 22.99

                • P/E Ratio 5-Year High

                • 35.65

                • 193.96

                • P/E Ratio 5-Year Low

                • 13.44

                • 87.26

                • Price/Sales Ratio

                • 5.52

                • 3.84

                • Price/Book Value

                • 5.80

                • 3.83

                • Price/Cash Flow Ratio

                • 21.60

                • 14.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 18.10

                    (30.60)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • 7.71

                    (13.80)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • 12.81

                    (21.80)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • 96.00k

                  • 90.07k

                  • Inventory Turnover

                  • 2.55

                  • 2.46

                  • Asset Turnover

                  • 0.46

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  3.10B
                  Operating Margin
                  18.90
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  21.60
                  Ownership

                  Institutional Ownership

                  71.74%

                  Top 10 Institutions

                  31.64%

                  Mutual Fund Ownership

                  39.64%

                  Float

                  99.88%

                  5% / Insider Ownership

                  0.30%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Health Care Fund

                  •  

                    36,197,961

                  • 22.96

                  • 2.18

                  • VA CollegeAmerica Income Fund of America

                  •  

                    31,722,500

                  • -3.62

                  • 1.91

                  • Vanguard Total Stock Mkt Idx

                  •  

                    27,125,799

                  • 0.79

                  • 1.64

                  • Vanguard Five Hundred Index Fund

                  •  

                    17,211,971

                  • 0.28

                  • 1.04

                  • Vanguard Institutional Index Fund

                  •  

                    16,796,307

                  • -1.01

                  • 1.01

                  • SPDR® S&P 500 ETF

                  •  

                    16,539,310

                  • 1.43

                  • 1.02

                  • VA CollegeAmerica Washington Mutual

                  •  

                    16,345,400

                  • 0.00

                  • 0.99

                  • Vanguard Wellington™

                  •  

                    13,804,990

                  • 32.97

                  • 0.83

                  • BlackRock Equity Dividend Fund

                  •  

                    9,989,070

                  • -1.75

                  • 0.60

                  • VA CollegeAmerica American Balanced

                  •  

                    9,950,000

                  • -10.76

                  • 0.60

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wellington Management Company, LLP

                  •  

                    119,946,967

                  • +34.52%

                  • 7.23

                  • Vanguard Group, Inc.

                  •  

                    84,156,909

                  • +2.40%

                  • 5.08

                  • Capital World Investors

                  •  

                    78,445,860

                  • -2.94%

                  • 4.73

                  • State Street Corp

                  •  

                    66,436,040

                  • +1.86%

                  • 4.01

                  • BlackRock Fund Advisors

                  •  

                    53,562,962

                  • +5.19%

                  • 3.23

                  • Fidelity Management and Research Company

                  •  

                    31,576,762

                  • -28.97%

                  • 1.90

                  • J.P. Morgan Investment Management Inc.

                  •  

                    25,406,144

                  • -0.17%

                  • 1.53

                  • Northern Trust Investments, N.A.

                  •  

                    24,628,793

                  • -0.10%

                  • 1.49

                  • Jennison Associates LLC

                  •  

                    23,675,401

                  • -18.42%

                  • 1.43

                  • T. Rowe Price Associates, Inc.

                  •  

                    16,744,454

                  • -5.15%

                  • 1.01

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Slow Growth

                  Style

                  Large Growth

                  Bristol-Myers Squibb Co, a Delaware corporation was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a bi...moreopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company’s pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes (typically involving recombinant DNA technology), called ‘biologics’. Small molecule drugs are typically administered orally, e.g., in the form of a pill or tablet, although other drug delivery mech...moreanisms are used as well. Biologics are typically administered to patients through injections or by infusion. Its revenues come from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience and metabolics. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company’s key products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others.The Company promotes its products directly to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and highly competitive. The Company competes with other research-based drug companies, many smaller research companies and generic drug manufacturers. The Company is subject to global regulation by regional, country, state and local agencies.lessless

                  Key People

                  Lamberto Andreotti

                  CEO/Director

                  James M. Cornelius

                  Director/Chairman of the Board

                  Mr. Charles A. Bancroft

                  CFO/Executive VP

                  Mr. Paul von Autenried

                  Chief Information Officer/Senior VP, Divisional

                  Mr. Francis M Cuss

                  Chief Scientific Officer/Executive VP

                  • Bristol-Myers Squibb Co

                  • 345 Park Avenue

                  • New York, NY 10154

                  • USA.Map

                  • Phone: +1 212 546-4000

                  • Fax: -

                  • bms.com

                  Incorporated

                  1933

                  Employees

                  28,000

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: